Clinical trials: Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer, Brain Metastases
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.
- Trial name
- NCT06476093
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- The First People's Hospital of Lianyungang
Non-Small Cell Lung Cancer, Brain Metastases
Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
1. Compare the effect and safety of gefitinib alone with gefitinib plus concomitant WBRT(whole-brain radiotherapy ) in treatment of NSCLC patients harboring an EGFR mutation with multiple BM. 2.
- Conditions
- Non-Small Cell Lung Cancer, Brain Metastases, EGFR Gene Mutation
- Trial name
- EGFR (NCT02338011)
- Testing
- Gefitinib, WBRT
- Where
- China
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Shanghai Chest Hospital
Multiple Brain Metastases, Non-small-cell Lung Cancer
Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study
1. Verify the effect of Erlotinib concurrent whole-brain radiation therapy as first-line treatment for patients with multiple brain metastases from non-small-cell lung cancer to compare with WBRT alone. 2.
- Trial name
- NCT01887795
- Testing
- Erlotinib, WBRT
- Where
- China
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University